Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. (NASDAQ: CDXS) generates news primarily around its enzymatic technologies for therapeutics manufacturing and the development of its ECO Synthesis® / ECO Synthesis™ manufacturing platform. The company’s announcements frequently highlight progress in applying enzyme-based processes to small molecule pharmaceuticals manufacturing and nucleic acid synthesis, as well as steps toward enabling scaled manufacture of RNAi therapeutics, including siRNA and other oligonucleotides, through enzymatic routes.
News about Codexis often covers financial results and business updates, where the company reports on revenues, product gross margins, research and development spending, and strategic priorities. These releases typically include commentary on the performance of its Pharma Biocatalysis business, the status of ECO Synthesis-related activities, and the company’s cash position and funding plans as disclosed in its quarterly and annual reporting cycles.
Another recurring theme in Codexis news is collaborations and evaluation agreements with organizations involved in oligonucleotide therapeutics. The company has announced agreements with CDMOs and CRDMOs such as Nitto Denko Avecia and Axolabs to evaluate the ECO Synthesis manufacturing platform for therapeutic siRNA and other oligonucleotides. These updates describe how partners assess Codexis’s enzymatic approach and indicate that such evaluations may lead to licensing discussions and broader adoption.
Codexis also issues news about infrastructure and strategic initiatives, including the signing of a lease for a GMP manufacturing facility in Hayward, California, intended to support GMP manufacturing of siRNA and other oligonucleotides using ECO Synthesis. Additional releases detail organizational changes, leadership transitions, workforce streamlining aligned with an enhanced focus on ECO Synthesis, and participation in industry conferences such as TIDES USA and TIDES Europe, where Codexis and its collaborators present data on enzymatic manufacturing technologies.
Investors and observers who follow CDXS news can use this stream of updates to monitor Codexis’s progress in advancing enzyme-based manufacturing platforms, its relationships with manufacturing partners, and its evolving strategic focus within therapeutics manufacturing.
Codexis (NASDAQ: CDXS) announced that the FDA has granted orphan drug designation and rare pediatric disease designation for its drug candidate CDX-6512, aimed at treating homocystinuria. This enzyme therapy is in pre-IND development and is positioned as a first-in-class oral treatment. The orphan designation provides incentives such as tax credits and potential marketing exclusivity for seven years upon FDA approval. Preclinical data showcasing CDX-6512 was previously presented at the ICIEM in November 2021.
Codexis, a prominent enzyme engineering company, will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference, scheduled from January 10-13, 2022. The event will take place virtually, allowing investors and interested parties to access a webcast starting January 10 at 7:00 a.m. ET. This presentation will be archived for 90 days on the company's website. Codexis utilizes its CodeEvolver® platform to enhance enzyme performance across pharmaceuticals, food, and industrial applications, showcasing its commitment to sustainable practices and health improvements.
Codexis, a prominent enzyme engineering company, announced the launch of its Codex® HiTemp Reverse Transcriptase, designed for one-step quantitative reverse transcription PCR (RT-qPCR) applications. This enzyme addresses critical challenges in viral diagnostics, including those for SARS-CoV-2. Key features include enhanced thermostability up to 70°C, improved robustness against clinical sample degradation, and a rapid turnaround time of five minutes for reverse transcription reactions. The enzyme is now available for bulk supply, supporting the ongoing demand for efficient viral RNA detection.
Codexis, Inc. (NASDAQ: CDXS) announced key advancements in biotherapeutic programs targeting homocystinuria (HCU) and maple syrup urine disease (MSUD) at the 14th International Congress of Inborn Errors of Metabolism in Sydney. CDX-6512 demonstrated up to 45% suppression of serum homocysteine in HCU mice, while a leucine decarboxylase showed similar results in MSUD models. Codexis aims to develop these gastrointestinal-stable enzymes as oral therapies, potentially improving treatment options for patients constrained by dietary restrictions. The company remains optimistic about further clinical advancements.
Codexis, a leading enzyme engineering company, announced participation in three upcoming virtual investment conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference features an on-demand fireside chat starting November 22, 2021, at 10:00 a.m. ET. The Stephens Annual Investment Conference will host its fireside chat on November 29, 2021, at 2:00 p.m. ET, followed by the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021, at 4:45 p.m. ET. Webcasts will be available for 30 days on the company’s website.
Codexis has appointed Karen Frechou-Armijo as Senior Vice President of Human Resources and Asli Aras, Ph.D., as Vice President of Corporate Development. Frechou-Armijo brings extensive HR experience, previously growing employee numbers at Cepheid significantly. Dr. Aras, with a strong background in corporate development, will enhance Codexis’ inorganic growth strategy. Both executives report to John Nicols, President and CEO, who emphasized their roles in building a high-performance culture and advancing growth opportunities as Codexis prepares for a crucial year ahead.
Codexis (Nasdaq:CDXS) announced key presentations at the 14th International Congress of Inborn Errors of Metabolism 2021, highlighting potential treatments for homocystinuria and maple syrup urine disease. The oral presentations will take place on November 21, 2021, featuring CDX-6512, a methionine-gamma-lyase enzyme therapy for homocystinuria, and a bacterial leucine decarboxylase therapy for maple syrup urine disease. Both will be presented by Dr. Kristen Skvorak, emphasizing innovative drug development efforts by Codexis to leverage synthetic biology.
Codexis (Nasdaq: CDXS) announced participation in three upcoming virtual investment conferences on November 16-18, 2021, showcasing its leading enzyme engineering capabilities. The events include the 12th Annual Craig-Hallum Alpha Select Conference, the Stifel 2021 Virtual Healthcare Conference, and the Jefferies London Healthcare Conference with scheduled 1x1 meetings and fireside chats. Webcasts will be available on Codexis' Investor Relations webpage for 30 days post-event. Codexis' innovations in enzyme technology aim to enhance sustainable manufacturing and biotherapeutics.
Codexis, Inc. (Nasdaq:CDXS) reported impressive financial results for Q3 2021, with total revenues reaching $36.8 million, a 100% increase from Q3 2020. Product revenues surged 242% to $28.7 million, driven by significant enzyme sales for Pfizer's COVID-19 antiviral candidate. The company achieved a record product gross margin of 76%. Codexis reiterated its total revenue guidance for FY 2021 at $98-103 million and raised product revenue guidance to $63-66 million. The company continues to expand its collaborations, including new agreements with Merck and Kalsec.
Codexis (CDXS) announced a $10 million investment in Molecular Assemblies, Inc. (MAI) through the SynBio Innovation Accelerator, aimed at accelerating MAI's enzymatic DNA synthesis technology. This partnership, initiated in June 2020, seeks to make DNA synthesis more cost-effective.
Codexis is the second largest shareholder in MAI and has a board seat. The investment highlights Codexis' commitment to pioneering solutions in synthetic biology, necessary for enhancing DNA synthesis capabilities. The SynBio Innovation Accelerator supports early-stage companies with disruptive technologies in synthetic biology.